The limited number of approved inhibitors for clinical application can be attributed to toxicities associated with PI3K/mTOR inhibitors and their limited activity in the CNS, particularly in the context of brain tumors (Figure 2), and development of resistance. This evidence concerns the gene MTOR and brain neoplasm.